142 related articles for article (PubMed ID: 38170616)
1. Stability of Ocular Alignment After Teprotumumab Therapy in a Cohort of Patients With Thyroid Eye Disease and Baseline Diplopia.
Davis JB; Mudalegundi S; Henderson AD; Carey AR
J Neuroophthalmol; 2024 Jan; ():. PubMed ID: 38170616
[TBL] [Abstract][Full Text] [Related]
2. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease.
Mudalegundi S; Huang P; Henderson AD; Carey AR
J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
4. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
5. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
[No Abstract] [Full Text] [Related]
6. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab for the treatment of chronic thyroid eye disease.
Ugradar S; Kang J; Kossler AL; Zimmerman E; Braun J; Harrison AR; Bose S; Cockerham K; Douglas RS
Eye (Lond); 2022 Aug; 36(8):1553-1559. PubMed ID: 34244669
[TBL] [Abstract][Full Text] [Related]
8. Improvement of asymmetric thyroid eye disease with teprotumumab.
Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
[TBL] [Abstract][Full Text] [Related]
9. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease.
Hwang CJ; Rebollo NP; Mechels KB; Perry JD
Am J Ophthalmol; 2023 Dec; 263():152-159. PubMed ID: 38142982
[TBL] [Abstract][Full Text] [Related]
10. Teprotumumab for the treatment of thyroid eye disease.
Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
[TBL] [Abstract][Full Text] [Related]
11. Teprotumumab for chronic thyroid eye disease.
Ozzello DJ; Dallalzadeh LO; Liu CY
Orbit; 2022 Oct; 41(5):539-546. PubMed ID: 34060414
[TBL] [Abstract][Full Text] [Related]
12. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
13. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Strabismus Surgery Following Teprotumumab Therapy.
Hilliard G; Pruett J; Donahue SP; Velez FG; Peragallo JH; Ditta LC; Tavakoli M; Hoehn ME; Kuo AF; Indaram M; Kerr NC
Am J Ophthalmol; 2024 Jun; 262():186-191. PubMed ID: 38191066
[TBL] [Abstract][Full Text] [Related]
15. Teprotumumab for thyroid eye disease: early response is not required for benefit.
Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas RS
Eye (Lond); 2022 Jul; 36(7):1403-1408. PubMed ID: 34183792
[TBL] [Abstract][Full Text] [Related]
16. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators.
Douglas RS; Wang Y; Dailey RA; Harris GJ; Wester ST; Schiffman JS; Tang RA; Fowler B; Fleming J; Smith TJ
J Neuroophthalmol; 2021 Dec; 41(4):461-468. PubMed ID: 33417417
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
Subramanian PS; Cho RI; Kahana A
Curr Opin Ophthalmol; 2023 Nov; 34(6):487-492. PubMed ID: 37610428
[TBL] [Abstract][Full Text] [Related]
19. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
Douglas RS; Dailey R; Subramanian PS; Barbesino G; Ugradar S; Batten R; Qadeer RA; Cameron C
JAMA Ophthalmol; 2022 Apr; 140(4):328-335. PubMed ID: 35175308
[TBL] [Abstract][Full Text] [Related]
20. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]